ReviewCancer management and research2019

Efficacy and safety of programmed death 1 inhibitors in patients with advanced non-small cell lung cancer: a meta-analysis.

Yi Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.